Dr Bertrand Routy, M.D., Ph.D.

Université de Montréal, CRCHUM et Institut du cancer de Montréal
 
Complete Form : Dr Bertrand Routy

2014/10 - 2017/11   PhD. Université de Paris XI (Paris-Sud)

                                   

2012/9 - 2014/7        Residency, University of Toronto

                                   

2009/9 - 2012/7        Residency, McGill University

                                   

2005/9 - 2009/6        MD, Université de Montréal

                                   

2003/9 - 2005/6        BSc, McGill University

2019                  FRQS Clinician Scientist Junior 1 Ranked #1

2018                  ASCO Conquer Cancer Foundation Merit Award

2018                  Article of the year: La Recherche et de Science & Avenir

2017                  ASCO Conquer Cancer Foundation Merit Award

2017                  ASCO Genitourinary Conquer Cancer Foundation Merit Award

2014-2017    Philanthropia Foundation - Course of excellence in oncology

2014-2017    Townsend hematology research fellowship scholarship

2014-2017    Montreal General Hospital foundation research scholarships

  • 2019/10-2021/9 – Co-PI, Oncopole
  • 2019/10 – 2024/9 – PI, CIHR
  • 2020/1 - 2024/12 – Collaborator, Canadian Strategy Innovation
  • 2019/1- 2024/1- PI, Institut du Cancer de Montréal
  • 2020/1 - 2030/1 – Co-I, Horizon 2020-European commission
  • 2018/1 - 2021/1 – PI, CRCHUM
  • 2019/1 - 2020/1 – Co-PI, Quebec Astellas – Prostate Cancer Research Fund
  • 2019/1 - 2020/7 - Co-A, The Weston Family Microbiome Initiative
  • 2018/4 - 2019/4 – PI, ThéCell
  • 2018/3 - 2019/2 – PI, KCRNC-KCC-CUASF
  • 2019/06-2020/6 – PI, Vedanta Bioscience

Dr. Bertrand Routy MD,PhD is an assistant professor of hemato-oncology and the scientific director of the Immunotherapy and Microbiome laboratory at the Université de Montréal Research Center. Dr. Routy received his MD from the Université de Montréal in 2009 and went on to graduate from McGill University’s Internal Medicine program. He then completed a fellowship at the Princess Margaret Hospital, University of Toronto. Following his medical training, he obtained a PhD in immuno-oncology at the Gustave Roussy Cancer Campus in Paris under the supervision of Pr. Laurence Zitvogel in 2017.

 

Dr. Routy’s past work includes unraveling the deleterious impact of antibiotics on patients receiving immune checkpoint blockers (ICB). He also contributed to establishing that the gut microbiota composition has a major impact on ICB efficacy in non-small cell lung cancer and renal cell carcinoma. He has written and published several seminal papers in journals including Science, Immunity, Cell and Annals of Oncology.

 

Dr. Routy’s research focuses on manipulation of the gut microbiome in combination with immunotherapy to develop novel therapies and biomarkers in thoracic oncology.

  1. Meriem Messaoudene (PhD, post-doctoral fellow, meriem.messaoudene@umontreal.ca)

  2. Corentin Richard (PhD, post-doctoral fellow, corentin.richard@umontreal.ca)

  3. Khoudia Diop (PhD, post-doctoral fellow, khoudia.diop@umontreal.ca)

  4. Wiam Belkaid (PhD, scientific coordinator, wiam.belkaid.chum@ssss.gouv.qc.ca)

  5. Florent Cauchois (BSc, research assistant, cauchois.pro@gmail.com)

  6. Julie Malo (CCRP, research nurse, julie.malo.chum@ssss.gouv.qc.ca)

  7. Arielle Elkrief (MD, FRCPC, research fellow, arielle.elkrief@gmail.com)

  8. Myriam Benlaïfaoui (BSc, MSc student, myriambenlaifaoui12@gmail.com)

  9. Iris Mimpen (BSc, MSc student, mimpeniris@gmail.com)

  10. Julien Bertrand (BSc student, julien765bertrand@gmail.com)

  11. Lena Cvetkovic (MD, resident, lena.cvetkovic@umontreal.ca)

  1. Elkrief A et al. Efficacy of immune checkpoint inhibitors in elderly patients with non-small cell lung cancer: real-life data from multicentric cohorts in Canada and France. Geriatric Oncology. In press

  2. Fluckiger A et al. Cross-reactivity between MHC class I-restricted antigens from cancer cells and an enterococcal bacteriophage. Nature. Under revision

  3. Elkrief A et al. The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy – anew independent prognostic factor? Annals of oncology. 2019 PMID:31268133

  4. Messaoudene M et al. T cell bispecific anti bodies in node positive breast cancer: Novel therapeutic avenue for MHC class 1 loss variants Annals of oncology 2019 PMID:30924846

  5. Elkrief A et al. Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors. OncoImmunnology 2019 PMID: 30906663

  6. Chen J et al. Multiple remissions of exrtacavitary primary effusion lymphoma treated with a single cycle of liposomal doxorubicin in a patent infected with HIV Curr Oncol. 2018 PMID:30607128

  7. Elkrief A et al. The intimate relationship between gut microbiota and cancer immunotherapy. Gut Microbes 2018:PMID:30339501

  8. Fumet JD et al. Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy. Br J Cancer. 2018 PMID:30318514

  9. Messaoudene M et al. In bacteria veritas: pronostic role of intestinal microbiote in cancer therapy. Med Sci 2018 PMID:30230457

  10. Derosa L et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small cell lung cancer. Annals of oncology 2018 PMID: 29617710